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PENILAIAN RAWATAN MADU TUALANG DAN PROPOLIS TERHADAP 
MIKROFLORA FARAJ SEMASA RAWATAN KEMORADIOTERAPI PADA 
PESAKIT KANSER SERVIK PEMEREBAKAN SETEMPAT 
 
ABSTRAK 
 
Kanser serviks adalah kanser yang paling lazim terjadi dalam kalangan 
wanita. Rawatan piawai bagi penyakit ini terdiri daripada radioterapi, kemoterapi dan 
brakiterapi. Kemoterapi selalunya diberikan kepada semua pesakit kanser serviks. 
Kemoradioterapi sering dikaitkan dengan kesan sampingan. Kemoradioterapi 
menyebabkan sistem imun menjadi lemah dan kesan sampingannya adalah seperti 
keguguran rambut, hilang selera makan yang mana boleh mengganggu kebanyakan 
pesakit kanser serviks. Terdapat kekurangan pengetahuan dalam bidang mikrobiologi 
terhadap jangkitan bakteria semasa kesan sitotoksik kemoradioterapi tersebut. Kajian 
klinikal ini dijalankan untuk mengetahui kesan madu Tualang dan propolis pada 
pencilan bakteria flora faraj semasa kemoradioterapi. Kajian in vivo telah dimulakan 
untuk menilai pengurangan pertumbuhan bakteria semasa rawatan piawai 
kemoradioterapi terhadap pesakit kanser servik. Seramai 30 pesakit telah berjaya 
direkrut (15 pesakit dalam kumpulan kajian, 15 pesakit dalam kumpulan kawalan). 
Untuk kumpulan kajian, rawatan kemoradioterapi telah disertakan dengan rawatan 
apiterapi, sementara untuk kumpulan kawalan hanya menerima rawatan 
kemoradioterapi sahaja. Swab pada kawasan faraj tinggi dan cecair basuhan faraj 
tinggi telah dikumpulkan sebelum dan selepas kemoradioterapi. Dua sampel ini telah 
diproses untuk melihat kadar pertumbuhan bakteria selama lima minggu berturut-
turut terapi diberikan kepada pesakit. Perubahan dalam pertumbuhan bakteria telah 
xviii 
 
dibandingkan diantara lima minggu tempoh rawatan untuk mengenalpasti 
keberkesanan in vivo madu Tualang dan propolis. Berbagai jenis bakteria telah 
dipencilkan dan dikenalpasti daripada sampel-sampel, mencadangkan bahawa telah 
berlaku perubahan dalam ekosistem faraj. Penemuan daripada kajian ini juga 
menunjukkan madu Tualang dan propolis mempunyai potentsi sebagai rawatan 
komplimentari semasa rawatan kemoradioterapi dilakukan. Pengurangan dalam 
pertumbuhan bakteria boleh dilihat pada pesakit yang dirawat dengan madu Tualang 
dan propolis (kumpulan kajian) berbanding dengan pesakit yang tidak dirawat 
dengan madu Tualang dan propolis (kumpulan kawalan). Hasil dari kajian ini, madu 
Tualang dan propolis mempunyai potensi sebagai agen anti-bakteria untuk digunakan 
sebagai rawatan komplementari. Kesan antibakteria seterusnya dibuktikan secara in 
vitro dengan menggunakan bakteria yang dipencilkan secara langsung daripada 
pesakit kanser servik dalam kajian ini. Dua penanda immunologi telah dikaji iaitu 
tahap protein CRP dan bilangan sel limfosit CD4+, yang dibandingkan dengan kadar 
pertumbuhan bakteria. Kajian ini menunjukkan bahawa kedua-dua protein CRP (r=-
0.3, p≤0.05) dan sel CD4+ (r=-0.37, p≤0.05) tidak signifikan dengan kadar 
pertumbuhan bakteria. Tetapi untuk CRP protein, keputusan kajian menunjukkan 
hasil yang positif dan mungkin perlu dibuat kajian dengan lebih lanjut untuk 
kepastian kerana jumlah sampel yang sedikit bagi kajian ini. Bagi sel CD4+, ia tidak 
boleh digunakan sebagai penanda untuk mengesan jangkitan bakteria kerana ia 
terkesan dengan rawatan kemoradioterapi. Hasil daripada kajian ini, madu Tualang 
dan propolis boleh digunakan sebagai rawatan komplimentari untuk mencegah 
jangkitan bakteria semasa rawatan kemoradioterapi. Pengurangan dalam 
pertumbuhan bakteria dapat dilihat pada pesakit yang dirawat dengan madu Tualang 
dan propolis, selari dengan jumlah protein CRP didalam badan pesakit. 
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EVALUATION OF TUALANG HONEY AND PROPOLIS ON VAGINAL 
FLORA IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS 
UNDERGOING CHEMORADIOTHERAPY 
 
ABSTRACT 
 
Cervical cancer is the most common cancer among women. The standard 
treatment consists of radiotherapy, chemotherapy and brachytherapy. Chemotherapy 
is invariably administered to all cervical cancer patients. Chemoradiotherapy agents 
often associated with side effects. Chemoradiotherapy induced immune system is one 
of the side effects despite of the hair loss, lost appetite which affects cervical cancer 
sufferers mostly. There is lack of knowledge in the field of microbiology that should 
focus on bacterial infection during the cytotoxic treatment with chemoradiotherapy. 
This prospective clinical trial was conducted to elucidate the effect of Tualang honey 
and propolis on the changes of the vaginal flora isolation in the high vaginal area 
during chemoradiotherapy treatment period. The in vivo study was embarked on to 
evaluate the reduction of bacterial growth during the standard chemoradiotherapy to 
cervical cancer patients. A total of 30 patients were successfully recruited (15 study 
arm, 15 control arm). In the study arm group, chemoradiotherapy was supplemented 
with additional apitherapy treatment, while the control arm group only received the 
chemoradiotherapy. High vaginal swab and high vaginal wash were collected before 
and after chemoradiotherapy from recruited patients to quantitate the bacterial 
growth, for five consecutive weeks of treatment. The changes in the bacterial growth 
were compared between the five weeks of treatment to determine the in vivo’s 
efficacy of Tualang honey and propolis. Various types of bacteria were isolated and 
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identified from samples, suggesting the alteration occurred in the vaginal ecosystem. 
Finding from this study also demonstrated that Tualang honey and propolis has 
potential as complementary treatment during chemoradiotherapy. Inhibition of 
bacterial growth were noted in patients treated with Tualang honey and propolis 
(study arm) compared to the untreated patients (control arm). The antibacterial 
effects of Tualang honey and propolis were subsequently proved via in vitro studies 
using bacteria that were isolated directly from cervical cancer patients. Two 
immunological markers namely CRP protein level and lymphocyte CD4+ cell count 
were tested whether correlated with the bioburden of bacteria. Finding showed that 
both CRP protein level (r=-0.3, p≤0.05) and lymphocyte CD4+ cell count (r=-0.37, 
p≤0.05) were not significant with the bioburden of bacteria. But for CRP protein, the 
results still showed a good result, and maybe can be tested further to confirm its role 
due to the low sample size in this research. For CD4+ cells, it cannot be used as a 
marker to monitor the bacterial infections because it was affected by 
chemoradiotherapy. In this study, Tualang honey and propolis can be used as a 
complementary treatment to prevent any bacterial infections during 
chemoradiotherapy treatment. Bacterial growth reduction can be seen in patients 
treated with Tualang honey and propolis, parallel with CRP protein level in patient’s 
body. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Research background 
 
Cervical cancer is very common in women. When the cancer grows, they involve 
adjacent pelvic structures cause pain, hydronephrosis, discharge and bleeding. The 
growth is very often involved with bacterial infection which goes unnoticed. 
Bacterial infestation usually leadings to foul smelling discharge, pain, tissue edema 
leading to less vascularity of tumor causing hypoxia (Biswal et al., 2014). Hypoxia 
resulted in reduced effectiveness to radiation. Honey is a natural product which has 
wide-spectrum of activity including antibacterial properties (Estevinho et al., 2008; 
Gheldof & Engeseth., 2002; Irish et al., 2008; Swellam et al., 2003; Temaru et al., 
2007; Wang et al., 2002). Propolis or bee glue is also very effective against variety 
of bacteria commonly associated with vaginal infection (Pratsinis et al., 2010). In 
this study, Tualang honey and propolis were used as a complementary treatment 
during the routine cancer treatment using both chemotherapy and radiotherapy. 
 
Universiti Sains Malaysia (USM) is currently engaged in a study on Tualang honey 
as an alternative treatment for bacterial infection. Malaysian Tualang honey is 
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believed and has been proven by the previous studies to possess good antibacterial 
properties (Tan et al., 2009; Khoo et al., 2010). Thus, this provides an opportunity to 
conduct this study and to prove the in vivo antibacterial properties of the Malaysian 
Tualang honey. 
 
1.2 Literature Review 
 
1.2.1  Cervical cancer 
 
Cancer is the uncontrolled growth of cells coupled with malignant behaviour: 
invasion and metastasis (Hanahan et al., 2000). It is caused by the interaction 
between genetic susceptibility and environmental factors (Hodgson, 2008; Perera, 
1997). These factors lead to accumulations of genetic mutations in oncogenes (genes 
that promote cancer) and tumour suppressor genes (genes that help to prevent 
cancer), which gives cancer cells their malignant characteristics, such as uncontrolled 
growth (Kehe et al., 2009). 
 
Cervical cancer is the second most common malignancy among women worldwide 
including Malaysia (Ferlay et al., 2004; Lim et al., 2008), accounting for 527,624 
cases in 2012 and 560,505 new cases are estimated to occur in 2015 (Ferlay et al., 
2010). However, knowledge on the illness still low which resulted in poor attitude 
towards its prevention. A woman's cervix (the opening of the uterus at the top of the 
vagina) is covered by a thin layer of tissue made up of cells. Healthy cells grow, 
divide, and are replaced as needed. Cancer of the cervix occurs when these cells 
change (ACOG, 2015). Cancer cells divide more rapidly and they may grow into 
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deeper cell layers or spread to other organs. The cancer cells eventually form a mass 
of tissue called a tumor. It often takes several years for cervical cancer to develop.  
During this time, the cells on or around the cervix becomes abnormal. The cell 
changes that occur before cancer is present are called dysplasia or cervical 
intraepithelial neoplasia (CIN). Screening for cervical cancer is based on the 
presence of cytomorphologically abnormal epithelial cells. Cervical cancer initially 
grows locally within the anatomical extent of the cervix, followed by permeation to 
the parametrium and other pelvic viscera in addition to lymph node metastases. One 
of the factors is the local growth harbor bacterial growth in the vaginal cavity, 
leading to pelvic inflammatory disease and hydrometra.  
 
Globally, cervical cancer is very common cancer among women, and there has been 
a study done in developing countries where this type of cancer is the second most 
common virus related cancer (Parkin et al., 2002). A report in 2004 indicated that 
there were approximately 12,000 incidences of invasive cervical cancer with 3850 
deaths among American women (US Cancer Statistics Working Group, 2007). 
However, prevalence of cervical cancer reported by World Health Organization 
(WHO) in developing countries remains incomplete and fragmentary. Indeed, 
Garland et al., (2008) estimated that 52% of all cervical cancer cases occur in the 
Asia-Pacific and Australasia region. Moreover, the same study estimated that if the 
current rate of cervical screening remains unchanged in this region, there will be a 
62% increase in the burden of disease associated with cervical cancer by 2025. 
Malaysia is a fast-developing South-East Asian country with a medium level of GDP 
per capita and a significant burden of cervical cancer. In 2008, 76% of all cases were 
diagnosed in FIGO (International Federation of Gynecology and Obstetrics) stage 2 
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or higher (Othman et al., 2009). This is reflective of the fact that the Asia-Pacific 
region bears a disproportionate amount of the global burden associated with cervical 
cancer especially in Malaysia.  
 
The mortality rate in Malaysia due to cancer is approximately 8.4 per 100,000 which 
is similar to that of other countries in the region, such as Indonesia, Singapore and 
Thailand, but more than two-fold higher in comparison with Netherlands, United 
Kingdom and Finland (Othman et al., 2009). In Malaysia, cancer of the cervix most 
commonly occurred in all the major ethnic groups which are Malay, Chinese and 
Indian (Lim et al., 2002). Compared among the major races, Chinese women had the 
highest incidence for cervical cancer followed by Indian and Malay (National Cancer 
Registry, 2006) where the incidence rate increased with age after 30 years and has its 
peak at ages 60 to 69 years. In Malaysia also, cervical cancer is now becoming the 
second most common cancer and is the fourth common cause of death among women 
(Domingo et al., 2008). In 2006, the incidence rate of cervical cancer in Peninsula 
Malaysia was 12.2 (9.1%) per 100,000 women (National Cancer Registry, 2006), but 
in 2008, the incidence rate leveled up to 17.9 per 100,000 women (Globocan, 2008). 
 
Mikamo et al., (1999) in their study indicate that prevalence of bacterial vaginosis 
(BV) among patients with cervical cancer varies from 50-80 %. BV resulted due to a 
change in vaginal ecosystem, where lactobacilli dominate, normal flora is absent or 
greatly reduced, and replaced with a mixed, predominantly anaerobic flora, 
consisting of Gardnerella vaginalis, Mycoplasma hominis, Mobiluncus sp., 
Bacteroides sp., Prevotela sp., Peptostreptococcus sp., Fusobacterium sp., and 
Porphyromonas sp. (Georgijevic et al., 2000).  
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The Centers for Disease Control and Prevention (CDC), which is a part of the 
principal agency in the United States government for protecting the health and safety 
of all Americans and for providing essential human services, have recently included 
BV on their list of emerging infectious diseases (CDC, 2002). Even though bacterial 
growth will be reduced by 47 % during radiotherapy, 24% of the patients developed 
fever possibly due to bacterial pathogenesis after brachytherapy procedure (Choo et 
al., 2008). BV in cervical cancer induces inflammation, increase tissue pressure, and 
oxygenation thereby reduces radiation tolerance. 
 
1.2.2 Chemotherapy 
 
Chemotherapy is the treatment of cancer with one or more cytotoxic anti-
neoplastic drugs (chemotherapeutic agents) as part of a standardized regimen. In the 
broad sense, most chemotherapeutic drugs work by impairing mitosis (cell division), 
effectively targeting fast-dividing cells. As these drugs cause damage to cells, they 
are also called cytotoxic. Chemotherapy treatment is about using chemical and 
biological agents to treat cancer. Since the first dose of cytotoxic chemotherapy was 
given in 1942, hundreds of thousands of chemical and biological agents have been 
tested for their activity in destroying cancer cells (David et al., 2003). They prevent 
mitosis by various mechanisms for examples like damaging DNA and inhibition of 
the cellular machinery involved in cell division (Malhotra et al., 2003; Kehe et al., 
2009).  
 
One of the theories why these drugs can kill cancer cells is that they induce a 
programmed form of cell death known as apoptosis (Makin et al., 2000). As 
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chemotherapy affects cell division, tumours with high growth rates (such as acute 
myelogenous leukaemia and the aggressive lymphomas, including Hodgkin's 
disease) are more sensitive to chemotherapy, as a larger proportion of the targeted 
cells are undergoing cell division at any time. Malignancies with slower growth 
rates, such as indolent lymphomas, tend to respond to chemotherapy much more 
modestly (Corrie and Pippa, 2008).  
 
1.2.3 Radiotherapy 
 
Radiotherapy is the treatment of disease using radiation. Radiotherapy uses radiation 
such as x-rays, gamma rays, electron beams or protons, which to kill or damage 
cancer cells and stop them from continue growing and multiplying. It can be given in 
two ways which are by external radiotherapy (a machine from outside the body aims 
radiation beams towards the cancer and surrounding tissues where the cancer may 
have spread) and by internal radiotherapy or also called brachytherapy (a radiation 
source is put inside the body on or near the cancer area). The aim of radiotherapy is 
to destroy cancer cells with as little damage as possible to normal cells. With the 
right amount of treatment, cancer cells do not recover from radiotherapy. Meanwhile, 
damage to normal cells causes side-effects. Usually the normal tissue recovers 
quickly and the side-effects do not last long. Sometimes the damage takes longer to 
repair and the side-effects may prolong on patients. Radiotherapy is very specific and 
only affects the area that is being treated. It is unlike chemotherapy which can affect 
the cells in your entire body (Antoinette, 2009). 
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1.2.4 Apitherapy 
 
Apitherapy is a branch of alternative medicine that uses honey and bee product such 
as propolis. These apitherapy products are well-known potential natural agents that 
have been shown to have good antibacterial properties. It is recognized for its 
benefits in medical uses, due to evidence of its antibacterial properties, which inhibit 
a broad spectrum of bacterial species (Molan and Russell, 2001).  
 
Honey is still being used not only as a natural sweetener or for its nutritional values, 
but also as a curative agent especially for bacterial infection. This was proved in the 
past decade where it has been an increase in the use of traditional and 
complementary or natural systems of medicine (The Landmark Report, 1998; 
Wilkinson et al., 2001; Thomas et al., 2001). Physical characteristics of honey such 
as its high osmolarity and acidity of honey also contributed to its antibacterial 
properties (Basualdo et al., 2007). The content inside honey is a bundle collection of 
nectar from many sources of plants by honey bees and this natural product is well 
known for its high nutritional and prophylactic medicinal value (Abou El-Soud 
Neveen, 2012).  
 
The first discovery of antibacterial activity of honey was in 1892 (Dustmann, 1989), 
but due to the lack of scientific support, the medicinal purpose was very limited (Ali 
et al., 1991). Recently, honey has been scientifically tested and confirmed to possess 
functional and biological properties such as anti-oxidant, anti-inflammatory, anti-
bacterial, anti-viral, anti-ulcerative activities, anti-lipid and anti-cancer properties 
(Estevinho et al., 2008; Gheldof et al., 2002; Irish et al., 2008; Swellam et al., 2003; 
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Temaru et al., 2007; Wang et al., 2002). All of these properties are mainly attributed 
to the phenolic constituents such as flavonoids that have antioxidant properties and 
radical-scavenging activities. These flavonoids are observed in all types of honeys in 
different proportions depending on the geography, food source for the honeybee, and 
climate (Beretta et al., 2007; Hegazi et al., 2009; Viuda-Martos et al., 2008). 
Malaysian tualang honey is collected from the combs of Asian rock bees (Apis 
dorsata), which build their hives high up in the tualang tree (Koompassia excelsa). 
Tualang honey is used commonly as a medicinal product and as food in Malaysia. 
However, little scientific information about its microbiological properties has been 
published to date (Tan et al., 2009). 
 
Propolis is a hive product collected by honeybees from various floral plant sources. It 
is a hard, resinous material derived by bees from plant juices and used to seal 
openings in the hives. It was a long history of being used in folk medicine dating 
back to at least 300 BC (Ghisalberti, 1979) and also has been reported to possess 
various biological activities, namely anticancer, antioxidant, anti-inflammatory, 
antibiotic, antifungal and anti-hepatotoxic (Ghisalberti, 1979; Burdock, 1998). 
Propolis also contains pollen, resins and waxes and large amounts of flavonoids 
which are benzo-y-pyrone derivatives found in all photosynthesizing cells. 
Flavonoids have many biological effects in animal systems but have received 
relatively little attention from pharmacologists (Havsteen, 1983). There are lots of 
propolis in the market, and this propolis that used in this study were bought trusted 
resercher in France. In many clinical studies, honey and propolis were found to 
control infections, including surgical wound and respiratory tract infections (Grange, 
1990; Molan, 2002; Paul, 2007; Ramanauskiene, 2009). Both products have wide-
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spectrum of antibacterial activities. They also posseses cytostatic and anti-angiogenic 
properties and reduce inflammation (Banskota, 2002; Isla, 2009; Pratsinis, 2010).  
 
Most of the bacterial pathogens could be controlled with apitherapy including 
resistant organisms and there are many types of honey that can be found all over the 
world. Each honey has different antimicrobial potency depending on its sources 
either polyfloral or monofloral, types of bees and environmental conditions, as well 
as its harvesting processes and storage conditions (Sherlock et al., 2010). 
 
1.2.5 Microbiological ecology of vagina 
 
The vaginal ecosystem is a complex biosphere, which made up of variety of 
constituents existing in a delicate equilibrium of many types of bacteria that are 
constantly secreting and releasing metabolic products and cellular debris from the 
disruption of dying bacterial cells. This vaginal secretion contains a variety of 
compounds such as proteins, carbohydrates, urea and fatty acids (Sumawong et al., 
1952; Paavonen, 1983). While the host vagina is also constantly secreting metabolic 
products and cellular debris into the ecosystem (Sebastian, 2004). 
 
The vaginal microflora consists of among other organisms, Gram-positive and Gram-
negative aerobic, facultative and obligate anaerobic bacteria, which are non-
pathogenic and potentially pathogenic bacteria. In a healthy vaginal ecosystem, the 
microflora is dominated by Lactobacillus sp. (Sebastian, 2004). But when the 
ecosystem becomes disrupted or unbalanced, the pathogenic bacteria gain dominance 
and pose a potential threat to the individual's general health and this condition will 
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lead to BV (Sebastian 2004). BV may cause damage to the vaginal epithelium by 
degrading the cervical mucus with proteases and changing the physicochemical and 
immunological environment of the vaginal niche, allowing the entry of pathogens 
(Rodriguez-Cerdeira et al., 2012). 
 
1.2.6 Cluster of differentiation 4 (CD4+) 
 
In molecular biology, CD4+ is a glycoprotein which can be found on the surface of 
immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It 
was discovered in the late 1970s and was originally known as leu-3 and T4 (after the 
OKT4 monoclonal antibody that reacted with it) before being named CD4 in 1984 
(Bernard et al., 1984). In humans, the CD4 protein is encoded by the CD4 gene 
(Isobe et al., 1986; Ansari et al., 1996). 
 
CD4+ T helper cells are white blood cells that are an essential part of the human 
immune system. They are often referred to as CD4+ cells, T-helper cells or T4 cells. 
They are called helper cells because one of their main roles is to send signals to other 
types of immune cells, including CD8 killer cells, which then destroy the infectious 
particle. If CD4+ cells become depleted, for example in untreated HIV infection, or 
following immune suppression prior to a transplant, the body is left vulnerable to a 
wide range of infections that it would otherwise have been able to fight (Christophe 
et al., 2004). The role of CD4+ levels measured in this study is to see whether it can 
act as a suitable marker to monitor BV.  
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1.2.7 C-reactive protein (CRP) 
 
CRP is an acute phase protein present in low concentrations in healthy individuals 
(Price et al., 1999). Any pathological condition associated with invasive bacterial 
infection, inflammation or tissue destruction is accompanied by elevation of the CRP 
level in the patient’s serum. The rise in CRP levels is rapid, and increased levels can 
be detected within 6 to 12 hours of the onset of the inflammatory process (van 
Leeuwen et al., 1994). 
 
These acute phase protein synthesized in the liver. Production of CRP is rapidly 
induced in response to infection, inflammation and tissue injury. Measurement of 
CRP may be helpful in the clinical management of a patient with symptoms of an 
infection. When evaluated in the light of the patient’s clinical condition, 
measurement of CRP can assist healthcare professionals in differentiating between 
bacterial and viral infections and in rationalising antibiotic therapy. Monitoring CRP 
levels also provides an objective means for assessing treatment response, as CRP 
levels fall rapidly as a result of an effective therapy. 
 
Quantitative measurement of the CRP concentration has been reported to be a 
sensitive indicator of the efficacy of antimicrobial therapy and the course of bacterial 
infections, as well as an effective tool in controlling and monitoring postoperative 
infections (van Leeuwen et al., 1994; Olaison et al., 1997; Peltola et al., 1997; Philip 
et al., 2000; Pepys, 2003). CRP levels were measured in this study to determine 
whether it has potential as a marker for BV detection. 
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1.3 Purpose of the study 
 
This prospective study is conducted to observe the local application of Tualang 
honey as vaginal packing and propolis vaginal pessary would completely inhibit 
bacterial growth from the high vaginal area in the study arm of patients compared to 
control arm patients, on the prevention of BV in invasive cervical cancer patients 
undergoing concurrent chemoradiotherapy. 
 
1.4 Hypothesis 
 
Tualang honey and propolis can inhibit the growth of the vaginal flora during 
chemoradiotherapy treatment in locally advanced cervical cancer. 
 
1.5       Specific objectives 
 
1)  To determine the bioburden and to compare the bacterial growth between control 
arm and study arm of cervical cancer patients. 
2)  To determine the antibacterial activities of Tualang honey and propolis against 
bacteria isolated from cervical cancer patients via in vitro by using antimicrobial 
susceptibility testing (AST). 
3)  To quantitate and to correlate the C-reactive protein (CRP) and CD4+ cell 
(lymphocyte) in cervical cancer patients with the bioburden of bacteria. 
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Figure 1.1: An overview of the study design 
 
 
 
 
 
 
 
 
 
 
 
Study arm EBRT 45 Gy/20# + ICRT 
9Gyx2 + chemotherapy CDDP, 40 
mg/m2X4, Tualang honey packing + 
propolis pessary. 
Control arm 45 Gy/20# + ICRT 
9Gyx2 + chemotherapy CDDP, 
40 mg/m2X4. No supplementary 
treatment. 
Analysis of data: comparison on 
the difference of the treatment 
response between both groups. 
 
Invasive cervical cancers 
pooled from oncology clinic of 
HUSM (Stage FIGO-IB2-
IVA). 
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
 
2.1 Study design 
 
An in vivo and in vitro study was carried out to assess the antimicrobial activities of 
Tualang honey and propolis on a range of selected clinical bacterial strains isolated 
from cervical cancer patients. A total of 30 patients were successfully recruited (15 
study arm, 15 control arm). Patients were evaluated once a week day for consecutive 
five weeks period and samples were collected by appointed staff nurse. All collected 
samples were immediately sent to microbiology lab for processing to evaluate the 
bioburden, and blood samples for immunological indicators such as CD4+ and CRP 
levels were sent to immunology lab for processing. For CD4+ and CRP, samples 
were taken on the first, third and fifth week of the study period. Throughout the 
evaluation period, patients were advice not to take any medicine prescription in order 
to see the effectiveness of apitherapy given. The overview of the experimental design 
is as shown in Figure 2.1. 
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Figure 2.1: Research flowchart. 
 
Processing sample 
For vaginal washing fluid, ten-fold 
dilution was performed, and 100 µl from 
each dilution was spread on blood agar, 
and incubated overnight at 35 °C ±2°C. 
On the next day, the bacterial growth 
colonie was count (CFU/ml) 
 
High Vaginal Swab, inoculate 
sample on: 
- MacConkey 
- Blood Agar (Aerobic 
and anaerobic) 
- Chocolate Agar 
Culture plates were incubated 
overnight at 35°C ±2 °C  
Identification of the isolated bacteria was done by using phenotypic test, 
biochemical test and VITEK 2 
In vitro antibacterial determination. MIC was 
performed using broth microdilution method 
Stock Culture was done by inoculating bacterial colony into the Glycerol BHI 
medium, and will be stored at -40°C 
MBC was done by taking 10 µl of the culture 
medium from each test well (from the broth 
microdilution assays) which showed no apparent 
growth and was subcultured on a fresh blood 
agar (BA) 
For blood sample, 
test was done at 
immunology lab, to 
determine the level 
of the CRP protein 
and also CD4+ 
lymphocyte count 
Propolis sensitivity test was done 
using standard Kirby Bauer method 
Collection of samples (15 control arm, 15 study arm) 
 Vaginal Swab 
 Vaginal Wash 
 Blood 
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2.2 Materials 
 
2.2.1 In vivo study design and materials 
 
2.2.1.(a) Experimental human model 
 
This was a clinical trial study which targeted patients with cervical cancer stage Ib2 
to IVA. The state of the cancer was based on International Federation of Gynecology 
and Obstetrics (FIGO) staging of cervical carcinomas as decribed in Table 2.1. A 
total of 30 clinically diagnosed patients with cervical cancer, age between 25 to 75 
years were successfully recruited in this study. All patients were selected based on 
inclusion and exclusion criteria as described in the Table 2.2. The study was 
performed in the Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan 
where patients were recruited in Nuclear Medicine, Radiotherapy and Oncology 
Clinic.  
 
It was conducted for the duration of 3 years from June 2011 until December 2014. 
Patients were distributed into two arms, first was control arm where all patients were 
given standard procedure for chemoradiotherapy treatment. While for study arm, 
patients were also given the same standard chemoradiotherapy treatment as in control 
arm, but they were supplemented with apitherapy consisted of Tualang honey and 
propolis ovules or provules, the mixture of propolis, cocoa butter, and beeswax. 
 
 
 
17 
 
Table 2.1: FIGO staging of cervical carcinomas. 
Cancer Stage Description 
Stage I 
Cervical carcinoma 
confined to the cervix 
(disregard extension to 
the corpus) 
 Stage IA: Invasive carcinoma diagnosed 
only by microscopy; stromal invasion with 
a maximum depth of 5.0 mm measured 
from the base of the epithelium and a 
horizontal spread of 7.0 mm or less; 
vascular space involvement, venous or 
lymphatic, does not affect classification 
 Stage IA1: Measured stromal invasion ≤ 
3.0 mm in depth and ≤ 7.0 mm in horizontal 
spread 
 Stage IA2: Measured stromal invasion > 
3.0 mm and ≤ 5.0 mm with a horizontal 
spread ≤ 7.0 mm 
 Stage IB: Clinically visible lesion confined 
to the cervix or microscopic lesion greater 
than T1a/IA2 
 Stage IB1: Clinically visible lesion ≤ 4.0 
cm in greatest dimension 
 Stage IB2: Clinically visible lesion > 4.0 
cm in greatest dimension 
Stage II 
Cervical carcinoma 
invades beyond uterus 
but not to pelvic wall or 
to lower third of vagina 
 Stage IIA: Tumor without parametrial 
invasion 
 Stage IIA1: Clinically visible lesion ≤ 4.0 
cm in greatest dimension 
 Stage IIA2: Clinically visible lesion > 4.0 
cm in greatest dimension 
 Stage IIB: Tumor with parametrial invasion 
Stage III 
Tumor extends to pelvic 
wall and/or involves 
lower third of vagina 
and/or causes 
hydronephrosis or 
nonfunctional kidney 
 Stage IIIA: Tumor involves lower third of 
vagina, no extension to pelvic wall 
 Stage IIIB: Tumor extends to pelvic wall 
and/or causes hydronephrosis or 
nonfunctional kidney 
Stage IV 
Tumor invades mucosa 
of bladder or rectum 
and/or extends beyond 
true pelvis (bullous 
edema is not sufficient to 
classify a tumor as T4) 
 Stage IVA: Tumor invades mucosa of 
bladder or rectum (bullous edema is not 
sufficient to classify a tumor as T4) 
 Stage IVB: Tumor extends beyond true 
pelvis 
Adopted from Cecelia et al., 2015. 
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Table 2.2: Inclusion and exclusion criteria. 
 
Inclusion Criteria Exclusion Criteria 
- Diagnosis of cervical cancer 
- Histopathological proof of 
squamous cell or 
adenocarcinoma 
- Age between 25 to 75 years 
- ECOG PS 0-1 
- Stage of cancer based on 
FIGO stageIb2-IVA 
- Adequate renal function 
- Small cell cervical cancer 
- Prior radiotherapy 
- Prior chemotherapy 
- Age < 25 years and >75 years 
- Uncontrolled medical condition 
- Pregnancy 
- Allergy or sensitivity to bee 
products 
- AIDS 
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2.2.1(b) Apitherapy materials (Tualang honey and propolis ovules) 
  
Local Malaysian Tualang honey (Agromas® pure Tualang honey) was supplied by 
the Federal Agriculture Marketing Authority (FAMA) Negeri Kedah Darul Aman, 
Malaysia. Tualang honey was subjected to sterilization by gamma-irradiation 
(25kGy) at Malaysia Nuclear Agency. These honey samples were obtained in the 
proper bottle container and kept in the laboratory at 20°C away from direct sunlight 
(Figure 2.2). Tualang honey was used as a supplement in study arm treatment 
directly after chemoradiotherapy treatment. 
 
 
Figure 2.2: Tualang honey and propolis pessary. 
 
Propolis ovules, also called provules, were made of mixture of propolis, cocoa butter 
and beeswax. The propolis was bought from the Bee Healthy Farm, USA, under 
consultation of Jean-François Lariviere (Figure 2.2). These provules were kept in 
room temperature before were used as a supplement in the study arm treatment 
directly after chemoradiotherapy treatment. 
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2.2.2 Instruments and apparatus  
 
Various instruments and apparatus used in this study were listed in the Table 2.3. 
These instruments were situated in the Medical Microbiology and Parasitology 
Laboratory, Central Research Laboratory and Immunology Laboratory, School of 
Medical Sciences, Universiti Sains Malaysia (USM).  
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Table 2.3: List of instruments and apparatus used for this study. 
 
Name Manufacturer 
Biological Microscope CX31 Olympus Corporation, Japan 
Bunsen burner (FIREBOY) INTEGRA Biosciences, Switzerland 
Class II Biological Safety Cabinet NuAire, USA 
CO2 Incubator Forma Scientific, USA 
DensiCHEK plus bioMérieux, USA 
Dispensette bottle-top dispensers BRAND, Germany 
O2 Incubator Memmert, Germany 
PhoenixSpecNephelometer Becton Dickinson, USA 
Test tube with screw-neck, borosilicated 
glass 
KIMBLE Chase, USA 
VITEK 2 Automated Microbial 
Identification System 
bioMérieux, USA 
Vortex REAX top Heidolph Instruments, Germany 
Thermoscientific Varioskan Flash Thermo Fisher Scientific, USA 
Quickread CRP Instrument Orion, Finland 
Flow Cytometer FACSCanto II Becton Dickinson BD, USA 
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2.2.3 Consumables 
 
All media and consumables used in this study are research grade (Table 2.4). 
 
Table 2.4: Details of media and consumables used in this study. 
Name Manufacturer 
Alcohol based hand rub (70%) Pharmacy, Hospital USM 
Vaginal speculum Mediscience Sdn. Bhd. 
Malaysia 
Amies Transport Medium with Charcoal (ready-
made) 
LabChem Sdn. Bhd., Malaysia 
Anaerogen compact 
Oxoid Ltd., United Kingdom 
Chocolate blood agar with horse blood plate 
(ready-made) Oxoid Ltd., United Kingdom 
Columbia horse blood agar plate (ready-made) 
Oxoid Ltd., United Kingdom 
Disposable sterile pipette 
Oxoid Ltd., United Kingdom 
Microscopic glass slide (frosted end) Ideal Healthcare Sdn. Bhd., 
Malaysia 
Mueller Hinton  agar plate (ready-made) 
Oxoid Ltd., United Kingdom 
Nugard prepowdered examination gloves Sun Healthcare Sdn, Bhd., 
Malaysia 
Peptone water (3 ml) 
Oxoid Ltd., United Kingdom 
Wilkins-Chalgren agar (WCA) 
(Neogen Corporation, USA 
Wilkins-Chalgren broth (WCB) 
(Neogen Corporation, USA) 
Plastic pouch 
Oxoid Ltd., United Kingdom 
Surgical Scrub 4% Steriline Sdn. Bhd. Malaysia 
Vitek 2 GN ID test card bioMérieux, USA 
Vitek 2 GP ID test card 
Vitek 2 AN ID test card 
bioMérieux, USA 
bioMérieux, USA 
BDMultitest™ IMK kit Becton Dickinson BD, USA 
QuickRead CRP kit  Orion, Finland 
NuncTM MicroWellTM 96 well microplates Thermo Scientific, USA 
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2.2.4 Media and reagents for microbiological analysis 
 
2.2.4(a) Horse blood agar (HBA)  
 
Ready to use enrichment media plates of horse blood agar (Cat. No. PB0114, Oxoid, 
Ltd, England) was used for the cultivation of fastidious bacteria and other 
microorganisms, an enrichment media.  
 
2.2.4(b) Chocolate horse blood agar (CBA) 
 
Ready to use media plates of chocolate horse blood agar (Cat. No. PB0124, Oxoid, 
Ltd, England) was used for the cultivation of fastidious bacteria and other 
microorganisms.  
 
2.2.4(c) MacConkey agar No. 3 (MAC) 
 
This agar was prepared by suspending 51.5 gm of MacConkey powder (Cat. No. 
CM0115, Oxoid, Ltd., England) in 1 L of distilled water and was boiled to dissolve 
completely. It was then sterilized by autoclaving at 121°C for 15 minutes. The 
mixture was left to cool to 60°C before pouring approximately 15 ml of the agar into 
sterile petri dishes. The agar was left to cool and harden completely at room 
temperature and incubated at 35°C ± 2°C for 24 hours (for quality control to check 
the sterility of the plates). 
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2.2.4(d) Wilkins-Chalgren broth (WCB) 
 
Preparation was made by suspending 33 gm of WCB powder (Code No. 7233A) 
from Acumedia Manufacturers (Neogen Corporation, USA) in 1 L of distilled water. 
The mixture was boiled until completely dissolved and sterilized at 121°C for 15 
minutes by autoclaving. The broth was left to cool and incubated at 35°C ± 2°C for 
24 hours (quality control) before stored in cold room at 5°C and ready to use.   
 
2.2.4(e) Wilkins-Chalgren agar (WCA) 
 
Preparation was made by suspending 33 gm of WCB powder (Code No. 7233A) 
from Acumedia Manufacturers (Neogen Corporation, USA) and 15 gm agar powder 
(Oxoid Ltd, England) in 1 L of distilled water. The mixture was boiled until 
completely dissolved. Sterilization was done by autoclaving at 121°C for 15 minutes. 
The mixture was left to cool to 60°C before pouring approximately 15 ml of agar 
into sterile empty petri dishes. The agar was left to cool and harden completely at 
room temperature and incubated at 35°C ± 2°C for 24 hours (quality control) before 
stored in cold room at 5°C and ready to use.   
 
2.2.4(f) Tryptone soy broth (TSB) 
 
Preparation was made by suspending 30 gm of TSB powder (Oxoid Ltd, England) in 
1 L of distilled water. The mixture was boiled until completely dissolved. 
Sterilization was done by autoclaving at 121°C for 15 minutes. The broth was left to 
